Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: A Danish nationwide population-based cohort study

BMJ Open

Volumn 6, Issue 5, 2016, Pages

  Green, Anders ^a,b   Pottegård, Anton ^c   Broe, Anne ^c   Diness, Thomas Goldin ^d   Emneus, Martha ^b   Hasvold, Pål ^d   Gislason, Gunnar H ^e  

^a Institute of Applied Economics and Health Research   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d ASTRAZENECA R AND D   (Sweden)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; WARFARIN; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DANISH CITIZEN; DENMARK; DIABETES MELLITUS; DUAL ANTIPLATELET THERAPY; FEMALE; GROUPS BY AGE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; PRESCRIPTION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; HEART INFARCTION; MEDICATION COMPLIANCE; MIDDLE AGED; REGISTER; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADENOSINE; AGED; AGED, 80 AND OVER; ASPIRIN; COHORT STUDIES; DENMARK; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; REGISTRIES; TICLOPIDINE;

EID: 84971236521     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010880     Document Type: Article

References (29)

1. Dudas K, Lappas G, Rosengren A. Long-term prognosis after hospital admission for acute myocardial infarction from 1987 to 2006. Int J Cardiol 2012;155:400-5.
2. Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091-4.
3. Gulliksson M, Wedel H, Köster M, et al. Hazard function and secular trends in the risk of recurrent acute myocardial infarction: 30 years of follow-up of more than 775 000 incidents. Circ Cardiovasc Qual Outcomes 2009;2:178-85.
4. Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011;305:1677-84.
5. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
6. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-619.
7. Sørensen R, Gislason GH, Fosbøl EL, et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008;66:875-84.
8. EMA (2015-08-11) Ticagrelor (Brilique) Summary of product characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/001241/WC500100494.pdf (accessed 1 Sep 2015).
9. EMEA (2014-02-17) Prasugrel (Efient) Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000984/WC500021971.pdf (accessed 1 Jun 2015).
10. The national Danish ACS guidelines. http://nbv.cardio.dk/ (accessed 1 Jun 2015).
11. Thygesen LC, Ersbøll AK. Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health 2011;39:8-10.
12. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39:38-41.
13. Anatomic Therapeutic Chemical (ATC) index. http://www.whocc.no/filearchive/publications/1-2013guidelines.pdf (accessed 1 Jun 2015).
14. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39:30-3.
15. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39:22-5.
16. Thygesen LC, Daasnes C, Thaulow I, et al. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 2011;39:12-16.
17. Nordic Medico-Statistical Committee: Classification of Surgical Procedures, version 1.15. Copenhagen, Denmark 2010: Publication 93.
18. Gislason GH, Rasmussen JN, Abildstrøm SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-8.
19. Mårtensson S, Gyrd-Hansen D, Prescott E, et al. Trends in time to invasive examination and treatment from 2001 to 2009 in patients admitted first time with non-ST elevation myocardial infarction or unstable angina in Denmark. BMJ Open 2014;4:e004052.
20. Fokkema ML, James SK, Albertsson P, et al. Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JAm Coll Cardiol 2013;61:1222-30.
21. Vamos EP, Millett C, Parsons C, et al. Nationwide study on trends in hospital admissions for major cardiovascular events and procedures among people with and without diabetes in England, 2004-2009. Diabetes Care 2012;35:265-72.
22. SWEDEHEART 2014 Annual Report (English edition). http://www.ucr.uu.se/swedeheart/index.php/arsrapporter (accessed 18 May 2015).
23. Erne P, Gutzwiller F, Urban P, et al. Characteristics and outcome in acute coronary syndrome patients with and without established modifiable cardiovascular risk factors: insights from the nationwide AMIS Plus Registry 1997-2010. Am J Cardiol 2013;111:202-7.
24. Bajaj RR, Goodman SG, Yan RT, et al. Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). Am J Cardiol 2013;111:202-7.
25. Jortveit J, Govatsmark RE, Digre TA, et al. Myocardial infarction in Norway in 2013. Tidsskr Nor Laegeforen 2014;134:1841-6.
26. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015;36:1163-70.
27. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
28. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
29. Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449-90.